The global chemotherapy market is gaining momentum as cancer treatment requirements, oncology infrastructure expansion, and pharmaceutical research create demand for anticancer medicines. Chemotherapy remains an important treatment approach across several cancer types, with established drugs and combination regimens continuing to play a role in clinical care. According to Straits Research, the global chemotherapy market was valued at USD 28.73 billion in 2025 and is projected to reach USD 67.03 billion by 2034, registering a CAGR of 9.87% during 2026–2034.
Key Market Highlights:
Market Size (2025): USD 28.73 Billion
Market Size (2026): USD 31.57 Billion
CAGR (2026–2034): 9.87%
Forecast Year: 2034
Projected Market Size (2034): USD 67.03 Billion
Dominant Region: North America
Fastest-Growing Region: Asia Pacific
Chemotherapy uses anticancer medicines to destroy cancer cells, restrict their spread, and slow disease progression. Treatments include drug categories such as alkylating agents and mitotic inhibitors, administered through oral and intravenous routes. Hospitals, specialty oncology centres, and research institutions remain important users of chemotherapy medicines across different treatment settings.
The expansion of oncology treatment infrastructure is improving access to chemotherapy services. India's Ministry of Health and Family Welfare reported the establishment of 524 Day Care Cancer Centres and 770 District NCD Clinics as of July 2026. These facilities create additional requirements for anticancer medicines, infusion equipment, and supportive care products.
Demand for affordable cancer treatment also encourages the adoption of generic chemotherapy drugs. The U.S. FDA approved 689 generic drug applications in FY2025, reflecting continued activity across the broader generic pharmaceutical sector. Generic paclitaxel and carboplatin remain important examples of cost-conscious treatment options.
Severe treatment-related side effects, high treatment expenses, and complications associated with chemotherapy can restrict treatment accessibility and patient adherence. Drug toxicity also requires careful monitoring and additional supportive care.
However, generic chemotherapy portfolios, personalized dose optimization, and combination treatment development offer new opportunities. Pharmaceutical manufacturers can also explore oral formulations and supportive medicines that address treatment-related complications.
By drugs, alkylating agents dominated with a 27.6% share in 2025. Mitotic inhibitors are projected to register the highest CAGR of 7.64% through 2034.
By indication, breast cancer accounted for 21.6% of the market in 2025, while lung cancer is projected to record the fastest CAGR of 7.74%.
By route of administration, oral chemotherapy is expected to register an 8.12% CAGR. By end user, hospitals dominated with a 72.8% share in 2025, while research institutes are projected to record the highest CAGR of 7.89%.
North America dominated the global market with a 41.2% share in 2025. The U.S. and Canada represent important markets due to their established oncology infrastructure and substantial cancer treatment requirements.
Asia Pacific is projected to register the fastest CAGR of 8.96% during the forecast period. China, Japan, and India offer significant opportunities through expanding cancer care requirements, ageing populations, and greater access to oncology treatment services.
Europe is projected to record a CAGR of 6.51%, with Germany and the U.K. representing important markets for chemotherapy medicines and specialized cancer care.
The market features multinational pharmaceutical companies, oncology drug developers, and generic medicine manufacturers competing through product portfolios, clinical research, and distribution capabilities. Key companies include:
Roche
Bristol Myers Squibb
Pfizer
Merck & Co.
Novartis
In February 2025, a feasibility study published in npj Precision Oncology evaluated the CURATE.AI platform for personalized chemotherapy dosing across capecitabine-based treatment approaches.
In March 2025, the U.S. FDA approved pembrolizumab in combination with trastuzumab and chemotherapy for eligible patients with HER2-positive gastric or gastroesophageal junction cancer. The approval reflected continued development of combination treatment approaches in oncology.
The chemotherapy market is expected to benefit from wider oncology treatment access, generic drug availability, and continued pharmaceutical research through 2034. Personalized dosing approaches, combination regimens, and oral chemotherapy formulations are likely to create additional opportunities for drug manufacturers and research institutions.
Click Here to Access the Comprehensive Report:https://straitsresearch.com/report/chemotherapy-market
Straits Research is a global market intelligence and consulting company that provides industry insights, market analysis, and strategic research solutions. The company delivers data-driven reports to help businesses understand market developments, identify emerging opportunities, and make informed decisions across diverse industries.